UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 8-K

 


 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): April 8, 2016 (April 5, 2016)


 

Protalix BioTherapeutics, Inc.

(Exact name of registrant as specified in its charter)

 


 

         
Delaware   001-33357   65-0643773

(State or other jurisdiction

of incorporation)

 

  (Commission File Number)  

(IRS Employer

Identification No.)

 

 

     
2 Snunit Street   20100
Science Park, POB 455    
Carmiel, Israel    
(Address of principal executive offices)   (Zip Code)

 

Registrant's telephone number, including area code +972-4-988-9488

 

 

(Former name or former address, if changed since last report.)

 


 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 


 

 

 

 

  

Item 8.01 Other Events

 

The Board of Directors of Protalix BioTherapeutics, Inc. (the “Company”) has elected to reschedule the Company’s previously announced 2016 Annual Meeting of Shareholders. The Company will announce the new date, time and related matters for the 2016 Annual Meeting of Shareholders after a final determination regarding those items has been made. The Company will subsequently file and mail proxy materials as required.

 

 

 

  

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

  PROTALIX BIOTHERAPEUTICS, INC.
     
Date: April 8, 2016 By: /s/ Moshe Manor
  Name: Moshe Manor
  Title: President and Chief Executive Officer

 

 

Protalix BioTherapeutics (AMEX:PLX)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Protalix BioTherapeutics Charts.
Protalix BioTherapeutics (AMEX:PLX)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Protalix BioTherapeutics Charts.